You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 147 No. 8, August 1987 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL INVESTIGATIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Reversible Adsorption (Desorption) of Aspirin From Activated Charcoal

Gay A. Filippone, PharmD; Susan S. Fish, PharmD; Peter G. Lacouture, PhD; Joseph M. Scavone, PharmD, MS; Frederick H. Lovejoy, Jr, MD

Arch Intern Med. 1987;147(8):1390-1392.


Abstract

• The potential desorption of aspirin from activated charcoal was investigated in eight patients in a randomized crossover study. Despite prebinding of aspirin, systemic absorption did occur. Desorption from activated charcoal was characterized by a peak salicylate concentration that was 16% of control and a time to peak salicylate concentration that was delayed in the study group. Bioavailability of aspirin from activated charcoal described by area under the curve was 19% of control. Elimination half-lives were similar in both groups until 12 hours after ingestion, but after 12 hours the half-life of the study group was prolonged while salicylate concentrations were undetectable in the control group. Fifteen percent to 20% of aspirin prebound to charcoal may desorb leading to systemic absorption. Furthermore, release from activated charcoal is initially delayed then sustained through 30 hours.

(Arch Intern Med 1987;147:1390-1392)



Author Affiliations

From the Department of Clinical Practice, Massachusetts College of Pharmacy and Allied Health Sciences (Drs Filippone, Fish, and Scavone); the Division of Clinical Pharmacology and Toxicology, The Children's Hospital (Drs Lacouture and Lovejoy); the Department of Pediatrics, Harvard Medical School (Dr Lovejoy); the Division of Clinical Pharmacology, New England Medical Center (Dr Scavone); and the Departments of Medicine and Psychiatry, Tufts University Medical School (Dr Scavone), Boston. Dr Filippone is now with Rutgers University College of Pharmacy, Piscataway, NJ; Dr Fish is with the Department of Emergency Medicine, Boston City Hospital.


Footnotes

Accepted for publication May 13, 1987.

Read in part before the annual meeting of the American Association of Poison Control Centers and the American Academy of Clinical Toxicology, Santa Fe, NM, Sept 29, 1986.

Reprint requests to Massachusetts Poison Control System, 300 Longwood Ave, Boston, MA 02115 (Dr Lacouture).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Desorption of Aspirin From Activated Charcoal
TENENBEIN
Arch Intern Med 1989;149:717-717.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1987 American Medical Association. All Rights Reserved.